Important Safety Information Prescribing Information Patient Site Request an Account Manager
Qlosi EyeQ Formulation
EYEQ FORMULATION™

Not all miotics
are created equal

Drops they dread don’t stick. Drops they love? That’s Qlosi

Low concentration meets high design

Not just a lower dose of what came before
EyeQ Formulation™: A formulation designed specifically for presbyopia, with the lowest effective concentration of any FDA-approved miotic.1-6

Designed to deliver
clear near vision1,4

And maintain an optimal pupil response7
Traditional miotics rely on higher concentrations driving stronger ciliary muscle engagement and increasing the potential for trade-offs.7
Clara T. holding Qlosi box
“
Qlosi takes a different approach
”
Qlosi 0.4% pilocarpine7:
Comparable to BSS control with no statistically significant change in ciliary muscle thickness (CMT)
2% pilocarpine7:
Demonstrated significant
increases in ciliary muscle thickness
This was a prospective, fixed-sequence crossover design with masked data analysis. The study enrolled 10 patients, recorded over 10,000 images.

BSS=balanced salt solution

Ciliary muscle thickness comparison: Qlosi 0.4% pilocarpine vs 2% pilocarpine
Supports accommodative demands with minimal ciliary muscle engagement7
Targeted approach7
Potentially reduce tractional forces associated with a high-concentration (2% pilocarpine) miotic7
Dr. Harmin Chima
“
So this data shows that Qlosi is ciliary [muscle] sparing, and that significantly reduces, in my opinion, the risk of retinal detachment. It gives me lot of confidence to have a conversation that really sets accurate expectations.”

→ Dr. Harmin Chima, OD Cleveland, OH

Don’t lose sight of the details

Near vision improvement without the need for higher concentrations.1,4,5,7
Low concentration icon
Lowest concentration of pilocarpine with 0.4% (4 mg/mL) of the active ingredient4
pH icon
Near-neutral pH solution increases bioavailability, helping to make it effective
at a minimum dose2,3
Lubricating agents icon
Dual lubricating agents
(HA and HPMC) to enhance
eye comfort1
Preservative-free icon
Preservative-free solution1
Qlosi single vial

Not actual size

HA=hyaluronic acid (aka sodium hyaluronate); HPMC=hydroxypropyl methylcellulose

More questions? See more

Formulation drives experience

Flexible by design

Plans shift. Schedules stretch. Qlosi offers dosing flexibility that meets your patients’ moments1
Qlosi carton and vial

Not actual size

Clear Start Week (first 7 days): 2x daily Qlosi1,4

Learn about the Clear Start Kit →
One drop of Qlosi in each eye for
up to 3 hours of clear near vision1
One drop Second drop
0 to 3 hours 3 to 8 hours Up to 8 hours
This drop can be repeated a second time in each eye after 2 to 3 hours for an effect up to 8 hours1

Indication and Usage

Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

Important Safety Information

Contraindications

Hypersensitivity

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

Qlosi is not recommended to be used when iritis is present.

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the instillation of Qlosi and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

Please see full Prescribing Information here: qlosiecp.com/prescribing-information

References

  1. Qlosi [package insert]. Ponte Vedra, FL. Orasis Pharmaceuticals.
  2. Anderson RA, Cowle JB. Influence of pH on the effect of pilocarpine on aqueous dynamics. Br J Ophthalmol. 1968;52(8):607-611. doi:10.1136/bjo.52.8.607
  3. Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine. J Pharm Sci. 1988;77(9):771-775. doi:10.1002/jps.2600770911
  4. Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  5. VUITY PI [package insert]. North Chicago, IL: AbbVie Inc.
  6. VIZZ PI [package insert]. Solano Beach, CA: LENZ Therapeutics, Inc.
  7. Cabot F. Miotic eyedrops for presbyopia: emerging therapies. Presented at Hawaiian Eye and Retina; Jan 17–23, 2026, Waikoloa Village, HI.